| Literature DB >> 33062301 |
Kerttu Toivo1,2, Pekka Kannus1, Sami Kokko3, Lauri Alanko4,5, Olli J Heinonen6, Raija Korpelainen7,8,9, Kai Savonen10,11, Harri Selänne12, Tommi Vasankari2, Lasse Kannas3, Urho M Kujala3, Jari Villberg3, Onni Niemelä13, Jari Parkkari1,2,14.
Abstract
OBJECTIVES: To compare laboratory test results and lung function of adolescent organised sports participants (SP) with non-participants (NP).Entities:
Keywords: Adolescent; Asthma; Iron metabolism; Sports & exercise medicine
Year: 2020 PMID: 33062301 PMCID: PMC7520547 DOI: 10.1136/bmjsem-2020-000804
Source DB: PubMed Journal: BMJ Open Sport Exerc Med ISSN: 2055-7647
Basic characteristics
| Boys (n=261) | Girls (n=317) | Total (n=578) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Sports participants (n=199) | Non-participants (n=62) | Coefficient (95% CI) | Sports participants (n=203) | Non-participants (n=114) | Coefficient (95% CI) | Sports participants | Non-participants (n=176) | Coefficient (95% CI) | |
| Age, mean | 15.7 | 15.7 | −0.02 (−0.17–0.12) | 15.6 | 15.6 | −0.03 (−0.15–0.09) | 15.6 | 15.6 | 0.00 (−0.09–0.09) |
| Weight, kg, mean | 64.5 | 62.5 | 0.03 (−0.01–0.08) | 58.3 | 59.8 | −0.03 (−0.06–0.01) | 61.4 | 60.8 | 0.01 (−0.02–0.04) |
| Height, cm, mean |
|
|
| 167 | 166 | 0.00 (−0.01–0.01) |
|
|
|
| BMI, mean | 20.8 | 20.6 | 0.01 (−0.03–0.05) | 20.9 | 21.7 | −0.04 (−0.06–0.01) | 20.9 | 21.3 | −0.02 (−0.04–0.00) |
Statistically significant results are indicated in bold.
Clinical laboratory data and iron supplement use
| Boys (n=261) | Girls (n=317) | Total (n=578) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Number of missing results in brackets | Participants (n=199) | Non-participants (n=62) | Coefficient/OR (95% CI) | Participants (n=203) | Non-participants (n=114) | Coefficient/OR (95% CI) | Participants (n=402) | Non-participants (n=176) | Coefficient/OR (95% CI) |
| Haemoglobin, mean (6) | 147 | 149 | −0.01 (−0.03–0.004) | 132 | 132 | −0.00 (−0.02–0.01) | 140 | 138 | 0.01 (−0.01–0.02) |
| Hb <120/130 | 7 (3.5) | 1 (1.6) | 1.34 (0.31–5.79) | 16 (8.1) | 8 (7.1) | 1.19 (0.49–2.92) | 23 (5.8) | 9 (5.1) | 1.20 (0.54–2.68) |
| Ferritin, mean, (17) | 47 | 44 | 0.08 (−0.07–0.24) | 31 | 32 | −0.03 (−0.19–0.13) | 39 | 36 | 0.08 (−0.04–0.19) |
| Ferritin <30, n, (%) | 49 (26.5) | 19 (30.2) | 0.76 (0.40–1.47) | 117 (60.3) | 62 (56.4) | 1.15 (0.71–1.86) | 166 (43.8) | 81 (46.8) | 0.86 (0.60–1.23) |
| Ferritin <15, n, (%) | 9 (4.9) | 5 (7.9) | 0.67 (0.23–1.99) | 44 (22.7) | 25 (22.7) | 1.02 (0.58–1.79) | 53 (14) | 30 (17.3) | 0.77 (0.47–1.27) |
| Transferrin receptor, mean (11) | 3.28 | 3.18 | 0.03 (−0.04–0.10) | 3.14 | 3.09 | 0.01 (−0.08–0.11) | 3.35 | 3.30 | 0.01 (−0.05–0.08) |
| Elevated transferrin receptor, n, (%) | 7 (3.7) | 1 (1.6) | 1.37 (0.32–5.97) | 29 (14.9) | 11 (10.0) | 1.52 (0.73–3.18) | 36 (9.4) | 12 (6.9) | 1.30 (0.67–2.51) |
| Use of iron supplement (%), (5) | 3 (1.5) | 0 | 1.30 (0.24–6.97) | 7 (3.5) | 0 | 1.75 (0.49–6.28) | 10 (2.5) | 0 | 1.56 (0.56–4.34) |
Allergies and asthma
| Boys (n=261) | Girls (n=317) | Total (n=578) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Number of missing results in brackets | Sports participants (n=199) | Non-participants (n=62) | OR (95% CI) | Participants (n=203) | Non-participants (n=114) | OR (95% CI) | Participants | Non-participants (n=176) | OR (95% CI) |
| Asthma in family, n, (%), (15) | 83 (43.2) | 30 (50.0) | 0.76 (0.43–1.37) | 99 (49.7) | 66 (58.9) | 0.69 (0.43–1.10) | 182 (46.5) | 96 (55.8) | 0.72 (0.50–1.03) |
| Regular use of allergy medication*, n, (%), (5) | 42 (21.3) | 13 (21.3) | 0.99 (0.49–2.00) | 39 (19.3) | 15 (13.3) | 1.51 (0.78–2.92) | 81 (20.3) | 28 (16.1) | 1.26 (0.78–2.05) |
| Regular use of asthma medication, n, (%), (5) | 16 (8.1) | 4 (6.6) | 1.20 (0.40–3.58) | 23 (11.4) | 5 (4.4) | 2.65 (0.97–7.27) | 39 (9.8) | 9 (5.2) | 1.74 (0.86–3.53) |
| Recurrent respiratory tract infections†, n, (%), (9) | 63 (32.1) | 21 (35.0) | 0.88 (0.48–1.62) | 80 (40.0) | 42 (37.2) | 1.13 (0.70–1.82) | 143 (36.1) | 63 (36.4) | 1.03 (0.71–1.50) |
| Recurrent skin rash, n, (%), (7) | 21 (10.7) | 10 (16.4) | 0.60 | 39 (19.4) | 31 (27.4) | 0.64 (0.37–1.11) |
|
|
|
| Dyspnoea during exertion, n, (%) (19) | 18 (8.4) | 9 (14.8) | 0.62 (0.26–1.46) | 45 (23.1) | 21 (18.8) | 1.30 (0.73–2.33) | 63 (16.3) | 30 (17.3) | 1.04 (0.64–1.69) |
| Pulmonary obstruction (FEV% z-score <−1.65, n, (%), (63) | 33 (18.9) | 13 (22.8) | 0.75 (0.36–1.56) | 25(14.1) | 12 (11.3) | 1.29 (0.62–2.71) | 58 (16.5) | 25 (15.3) | 1.07 (0.64–1.78) |
| Significant bronchodilator response (FEV1 or FVC ≥+12%, (84) | 13 (7.6) | 3 (5.6) | 1.43 (0.38–5.41) | 11 (6.4) | 7 (6.9) | 0.95 (0.37–2.43) | 24 (7.0) | 10 (6.4) | 1.17 (0.54–2.54) |
*Antihistamine in the spring, for example, nasal corticosteroid if used together with antihistamine, allergy eye medication, medication for hyposensitisation.
†Common cold, sore throat, rhinitis, bronchitis more than three times per year.
Statistically significant results are indicated in bold.